Read Larry Connors' blog – Short Term Trading Strategies
EnerDel Awarded $3.3 Million For Safety Research on Auto Lithium-ion Battery
Department of Energy Project Targets Cell R&D to Improve Charging Performance
INDIANAPOLIS, June 22, 2009 -- Advanced lithium-ion automotive battery developer EnerDel has been awarded up to $3.3 million for a cost-share research project under the U.S. Department of Energy. This will be the largest of a set of new projects announced under DOE's Vehicle Technologies Program, and will focus on the development of innovative technologies to eliminate overcharging in lithium-ion cells.
About EnerDel:
EnerDel, a subsidiary of Ener1, Inc. (Nasdaq: HEV), develops and manufactures compact, high performance lithium-ion batteries to power the next generation of hybrid, plug-in hybrid and pure electric vehicles. Led by an experienced team of engineers and energy system experts, the company is building proprietary innovations based on technology originally pioneered at the Argonne National Laboratory.
EnerDel produces its batteries at its state-of-the-art facilities in Indianapolis, Indiana, and is expecting to be the first company to mass-produce a cost-competitive lithium-ion battery for hybrid and electric vehicles. In addition to the automobile market, applications for EnerDel lithium-ion battery technology include medical, military, aerospace, electric utility and other growing markets.
-- Targeted Genetics Corporation (NASDAQ: TGEN) soared 20% trading on 935,010 shares.
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for a Gene Therapeutic to Treat Leber's Congenital Amaurosis and Provides Business Update
Initial Phase 1/2 Findings Demonstrated Acceptable Safety and Improvement in Visual Function; Protocol Amended to Increase Dose and Include Younger Children
SEATTLE, WA, Jun 22, 2009 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced that its collaborator at the University College London/Moorfields Eye Hospital (UCL/M) has begun the next step in its Phase 1/2 dose escalation clinical trial to treat a form of Leber's Congenital Amaurosis caused by defects in the gene encoding the RPE65 protein. Leber's Congenital Amaurosis, or LCA, is an inherited disease that typically results in blindness. Under an amended protocol to its Phase 1 /2 dose escalation clinical trial, UCL/M is approved to include younger LCA patients in the trial and treat patients with higher doses of an adeno-associated virus (AAV) vector containing the RPE65 gene.
About Targeted Genetics Corporation
Targeted Genetics Corporation is a biotechnology company committed to the development of innovative therapies for the prevention and treatment of diseases with significant unmet medical need. A key area of focus for Targeted Genetics is applying its proprietary Adeno-Associated Virus (AAV) technology platform to deliver genetic constructs to increase gene function or silence gene function. Targeted Genetics' lead product development efforts target ocular and neurological indications, two therapeutic areas where AAV delivery may have competitive advantages over other therapeutic modalities. To learn more about Targeted Genetics, visit its website at www.targetedgenetics.com.
-- Silicon Image, Inc. (NASDAQ:SIMG) traded at $2.33 with the volume of 127,413 shares
Silicon Image Introduces First Products Incorporating HDMI 1.4 Features for DTV and Home Theatre Applications
Devices Pave the Way for LiquidHD(TM) Applications and Services With Simple Connectivity Through Integrated HDMI(R) Ethernet Channel
SUNNYVALE, Calif., Jun 22, 2009 -- Silicon Image, Inc. (NASDAQ:SIMG), a leader in semiconductors and intellectual property for the secure distribution, presentation and storage of high-definition (HD) content, today introduced the SiI9387 port processor and the SiI9334 transmitter, the first semiconductor products to incorporate the latest HDMI(R) 1.4 specification features for digital television (DTV) and home theatre applications. The new devices offer a richer, more interactive HDMI(R) entertainment experience by enabling new connectivity applications via Ethernet, such as Silicon Image's LiquidHD(TM) technology.
About Silicon Image, Inc.
Silicon Image, Inc. is a leading provider of semiconductor and intellectual property products for the secure distribution, presentation and storage of high-definition content. With a rich history of technology innovation that includes creating industry standards such as DVI and HDMI, the company's solutions facilitate the use of digital content amongst consumer electronics, personal computer (PC) and storage devices, with the goal to securely deliver digital content anytime, anywhere and on any device. Founded in 1995, the company is headquartered in Sunnyvale, California, with regional engineering and sales offices in China, Germany, Japan, Korea, Taiwan and the United Kingdom. For more information, please visithttp://www.siliconimage.com/.
-- Oncothyreon Inc. (Nasdaq: ONTY) soared 17% traded at $2.669 with the volume of 573,863 shares
Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
SEATTLE, Jun 22, 2009 -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Stimuvax is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon.
http://pinksheets.com/pink/quote/quote.jsp?symbol=onty
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visitwww.oncothyreon.com.
About PicksThatMove.com
www.picksthatmove.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you.
www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@picksthatmove.com
www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
CONTACT: PicksThatMove.com e-mail: Info@picksthatmove.com WWW: http://www.picksthatmove.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
